|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Drug Abuse (NIDA) |
|---|---|
| Collaborator: |
University of Pennsylvania |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000187 |
Purpose
The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.
| Condition | Intervention | Phase |
|---|---|---|
|
Cocaine-Related Disorders |
Drug: Ritanserin |
Phase II |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Ritanserin in Treatment of Cocaine Dependence |
Eligibility| Ages Eligible for Study: | 28 Years to 47 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Pennsylvania | |
| University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 6178 | |
| Principal Investigator: | James Cornish, M.D. | University of Pennsylvania |
More Information
| ClinicalTrials.gov Identifier: | NCT00000187 History of Changes |
| Other Study ID Numbers: | NIDA-00144-1, K20-00144-1 |
| Study First Received: | September 20, 1999 |
| Last Updated: | August 16, 2005 |
| Health Authority: | United States: Federal Government |
|
Cocaine-Related Disorders Substance-Related Disorders Mental Disorders Ritanserin Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Central Nervous System Agents Therapeutic Uses Psychotropic Drugs Anti-Anxiety Agents Antidepressive Agents, Second-Generation Antidepressive Agents |